Sugar alcohol provides imaging contrast in cancer detection.
Algorithms
Animals
Blood-Brain Barrier
/ metabolism
Brain Neoplasms
/ diagnosis
Contrast Media
/ metabolism
Disease Models, Animal
Female
Glioma
/ diagnosis
Image Interpretation, Computer-Assisted
/ methods
Magnetic Resonance Imaging
/ methods
Maltose
/ analogs & derivatives
Phantoms, Imaging
Rats
Rats, Inbred F344
Sugar Alcohols
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 07 2019
31 07 2019
Historique:
received:
10
01
2017
accepted:
09
07
2019
entrez:
2
8
2019
pubmed:
2
8
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Clinical imaging is widely used to detect, characterize and stage cancers in addition to monitoring the therapeutic progress. Magnetic resonance imaging (MRI) aided by contrast agents utilizes the differential relaxivity property of water to distinguish between tumorous and normal tissue. Here, we describe an MRI contrast method for the detection of cancer using a sugar alcohol, maltitol, a common low caloric sugar substitute that exploits the chemical exchange saturation transfer (CEST) property of the labile hydroxyl group protons on maltitol (malCEST). In vitro studies pointed toward concentration and pH-dependent CEST effect peaking at 1 ppm downfield to the water resonance. Studies with control rats showed that intravenously injected maltitol does not cross the intact blood-brain barrier (BBB). In glioma carrying rats, administration of maltitol resulted in the elevation of CEST contrast in the tumor region only owing to permeable BBB. These preliminary results show that this method may lead to the development of maltitol and other sugar alcohol derivatives as MRI contrast agents for a variety of preclinical imaging applications.
Identifiants
pubmed: 31366892
doi: 10.1038/s41598-019-47275-5
pii: 10.1038/s41598-019-47275-5
pmc: PMC6668433
doi:
Substances chimiques
Contrast Media
0
Sugar Alcohols
0
Maltose
69-79-4
maltitol
D65DG142WK
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11092Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB015893
Pays : United States
Organisme : NIBIB NIH HHS
ID : T32 EB020087
Pays : United States
Références
Mol Oncol. 2008 Aug;2(2):115-52
pubmed: 19383333
Sci Rep. 2017 Feb 07;7:42093
pubmed: 28169369
Radiology. 2015 Jul;276(1):228-32
pubmed: 25942417
Cancer Res. 2016 Nov 15;76(22):6463-6470
pubmed: 27651313
NMR Biomed. 2012 Nov;25(11):1305-9
pubmed: 22431193
J Transl Med. 2017 May 30;15(1):119
pubmed: 28558795
Magn Reson Med. 2012 Dec;68(6):1764-73
pubmed: 23074027
Annu Rev Biomed Eng. 2008;10:391-411
pubmed: 18647117
Sci Rep. 2014 Aug 15;4:6081
pubmed: 25124082
Science. 2006 May 26;312(5777):1168-71
pubmed: 16728630
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Jan-Feb;5(1):1-18
pubmed: 23047730
J Cereb Blood Flow Metab. 2013 Aug;33(8):1270-8
pubmed: 23673434
J Magn Reson. 2010 Feb;202(2):155-61
pubmed: 19926319
Nat Rev Cancer. 2002 Sep;2(9):683-93
pubmed: 12209157
Sci Rep. 2013 Oct 25;3:3045
pubmed: 24157711
J Oncol. 2012;2012:710561
pubmed: 22973310
Brain Res. 2001 Mar 23;895(1-2):250-2
pubmed: 11259785
Magn Reson Med. 2015 Dec;74(6):1556-63
pubmed: 26404120
J Clin Invest. 1967 Apr;46(4):499-505
pubmed: 6021203
J Cereb Blood Flow Metab. 1990 Mar;10(2):170-9
pubmed: 1968068
Magn Reson Med. 2013 Mar 1;69(3):760-70
pubmed: 22577042
Magn Reson Med. 2017 Jul;78(1):215-225
pubmed: 27521026
NMR Biomed. 2008 Mar;21(3):208-16
pubmed: 17530617
Neuroimage. 2011 Feb 1;54(3):2079-85
pubmed: 20951217
NMR Biomed. 2013 Apr;26(4):386-91
pubmed: 23045158
J Nucl Med. 2010 Aug;51(8):1167-70
pubmed: 20660380
J Magn Reson. 2016 Sep;270:56-70
pubmed: 27404128
Sci Rep. 2018 Jun 22;8(1):9576
pubmed: 29934551
CA Cancer J Clin. 2012 Nov-Dec;62(6):364-93
pubmed: 23070605
Magn Reson Med. 2014 Nov;72(5):1375-80
pubmed: 25236979
Nat Med. 2012 Jan 22;18(2):302-6
pubmed: 22270722
Magn Reson Med. 2012 Apr;67(4):936-42
pubmed: 21842497
J Magn Reson. 2013 Apr;229:155-72
pubmed: 23273841
Magn Reson Med. 2014 Sep;72(3):823-8
pubmed: 24975029
Surgeon. 2014 Jun;12(3):148-57
pubmed: 24629841
Sci Rep. 2016 Jul 27;6:30618
pubmed: 27461165
Sci Rep. 2016 Sep 07;6:32648
pubmed: 27600054
Br J Nutr. 1982 Nov;48(3):477-81
pubmed: 7171535
Cancer Res. 1992 Mar 1;52(5):1259-66
pubmed: 1737388
J Biomol NMR. 2018 Oct;72(1-2):93-103
pubmed: 30203383
Curr Radiol Rep. 2013 Jun 1;1(2):102-114
pubmed: 23730540
Magn Reson Med. 2018 Feb;79(2):1001-1009
pubmed: 29193288
Magn Reson Med. 2018 Aug;80(2):488-495
pubmed: 29569739
Radiology. 2015 Jun;275(3):630-4
pubmed: 25942418
Magn Reson Med. 2009 Jun;61(6):1441-50
pubmed: 19358232
Nat Med. 2013 Aug;19(8):1067-72
pubmed: 23832090
Magn Reson Med. 2019 Jun;81(6):3798-3807
pubmed: 30793789
J Cereb Blood Flow Metab. 2018 May;38(5):869-880
pubmed: 28485194
Neuroimage. 2014 Nov 1;101:185-92
pubmed: 25003815
Invest Radiol. 2006 Mar;41(3):272-8
pubmed: 16481910
Contrast Media Mol Imaging. 2014 Jul-Aug;9(4):268-75
pubmed: 24706610
Magn Reson Med. 2018 Feb;79(2):1061-1069
pubmed: 28497566
Magn Reson Med. 2011 Apr;65(4):927-48
pubmed: 21337419